Evidence map›Paper›PMID 29137637›Full record

ArticleVirology journal2017

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.

Karolin Meixenberger, Kaveh Pouran Yousef, Maureen Rebecca Smith, Sybille Somogyi, Stefan Fiedler, Barbara Bartmeyer, Osamah Hamouda, Norbert Bannert, Max von Kleist, Claudia Kücherer

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Karolin MeixenbergerHIV and other Retroviruses, Robert Koch Institute, Berlin, Germany. meixenbergerk@rki.de.
Kaveh Pouran YousefDepartment of Mathematics and Computer Science, Freie Universität Berlin, Berlin, Germany.
Maureen Rebecca SmithDepartment of Mathematics and Computer Science, Freie Universität Berlin, Berlin, Germany.
Sybille SomogyiHIV and other Retroviruses, Robert Koch Institute, Berlin, Germany.
Stefan FiedlerHIV and other Retroviruses, Robert Koch Institute, Berlin, Germany.
Barbara BartmeyerHIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.
Osamah HamoudaHIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.
Norbert BannertHIV and other Retroviruses, Robert Koch Institute, Berlin, Germany.
Max von KleistDepartment of Mathematics and Computer Science, Freie Universität Berlin, Berlin, Germany.
Claudia KüchererHIV and other Retroviruses, Robert Koch Institute, Berlin, Germany.
Robert Koch Institute · DEFreie Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDetailed knowledge of the evolutionary potential of polymorphic sites in a viral protein is important for understanding the development of drug resistance in the presence of an inhibitor. We therefore set out to analyse the molecular evolution of the HIV-1 subtype B integrase at the inter-patient level in Germany during a 20-year period prior to the first introduction of integrase strand inhibitors (INSTIs).

methodsWe determined 337 HIV-1 integrase subtype B sequences (amino acids 1-278) from stored plasma samples of antiretroviral treatment-naïve individuals newly diagnosed with HIV-1 between 1986 and 2006. Shannon entropy was calculated to determine the variability at each amino acid position. Time trends in the frequency of amino acid variants were identified by linear regression. Direct coupling analysis was applied to detect covarying sites.

resultsTwenty-two time trends in the frequency of amino acid variants demonstrated either single amino acid exchanges or variation in the degree of polymorphy. Covariation was observed for 17 amino acid variants with a temporal trend. Some minor INSTI resistance mutations (T124A, V151I, K156 N, T206S, S230 N) and some INSTI-selected mutations (M50I, L101I, T122I, T124 N, T125A, M154I, G193E, V201I) were identified at overall frequencies >5%. Among these, the frequencies of L101I, T122I, and V201I increased over time, whereas the frequency of M154I decreased. Moreover, L101I, T122I, T124A, T125A, M154I, and V201I covaried with non-resistance-associated variants.

conclusionsTime-trending, covarying polymorphisms indicate that long-term evolutionary changes of the HIV-1 integrase involve defined clusters of possibly structurally or functionally associated sites independent of selective pressure through INSTIs at the inter-patient level. Linkage between polymorphic resistance- and non-resistance-associated sites can impact the selection of INSTI resistance mutations in complex ways. Identification of these sites can help in improving genotypic resistance assays, resistance prediction algorithms, and the development of new integrase inhibitors.

Indexed as

Evolution, MolecularPolymorphism, GeneticAdultAmino Acid SubstitutionAnti-HIV AgentsDrug Resistance, ViralFemaleGenotypeHIV-1HIV InfectionsHIV IntegraseHIV Integrase InhibitorsHumansMaleMutationSequence Analysis, DNAAnti-HIV AgentsHIV IntegraseHIV Integrase Inhibitorsp31 integrase protein, Human immunodeficiency virus 1CovariationDrug resistanceHIVIntegrasePolymorphismsTime trend

Identifiers

PMID29137637
PMCPMC5686839
OpenAlexW2769519365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.